Marcos-Parra María Teresa, Mendoza-Moreira Angi Lizbeth, Moreno-Castro Lucía, Mateos-Marcos Carlos, Salinas-López Javier Alejandro, Figuerola-García María Belén, González-Alonso Ángela, Pérez-Santonja Juan José
Department of Ophthalmology, Hospital General Universitario Balmis.
Clínica Oftalvist, Alicante.
J Glaucoma. 2022 Oct 1;31(10):826-833. doi: 10.1097/IJG.0000000000002090. Epub 2022 Aug 1.
Trabeculectomy (TRAB) surgery reduces the intraocular pressure (IOP) more than the XEN45 implant over 3 years. There is no difference in the number of antiglaucoma medications between the 2 procedures. The decision to perform either TRAB or XEN45 implantation must be evaluated on a case-by-case basis, taking into account the high rate of needling of the XEN45.
The aim of this study was to compare the differences between the efficacy and safety of the XEN45 implant and TRAB, either alone or in combination with phacoemulsification (PHACO), in patients with open angle glaucoma (OAG) at 36 months.
A retrospective, single-center and comparative study conducted on OAG patients who underwent XEN45 implantation or TRAB from 2016 to 2018. Patients were divided into 4 groups: group 1 (XEN45 alone), group 2 (XEN45+PHACO), group 3 (TRAB alone), and group 4 (TRAB+PHACO). For statistical purposes, groups 1 and 2 were combined (XEN45 implant), whereas groups 3 and 4 were also combined (TRAB surgery). IOP, number of glaucoma medications, and adverse events were evaluated. The main outcome measure was the reduction in IOP at 36 months postoperatively.
One hundred thirty-four patients (134 eyes; 63 XEN45 and 71 TRAB) were included. The mean (95% confidence interval) IOP reduction at the end of the study follow-up was -6.3 (-11.0 to -1.6 mm Hg, P =0.025, XEN45 alone), -8.9 (-11.0 to -6.8 mm Hg, P <0.001, TRAB alone), -2.5 (-4.5 to -0.4 mm Hg, P =0.019, XEN45+PHACO), and -5.6 (-7.7 to -3.4 mm Hg, P <0.001, TRAB±PHACO). The proportion of patients achieving an IOP≥6 and ≤16 mm Hg without treatment at the end of the 36-month follow-up were 50.8% (32/63) in the XEN45 implant and 49.3% (35/71) in the TRAB surgery group, P =0.863. The mean number of glaucoma medications was significantly reduced in all the study groups. The needling rate was 19% in XEN45 versus 5.6% in the TRAB group ( P =0.030), and 2.81% and 36.6% of eyes in the TRAB group presented anterior chamber flattening and hyphema, respectively.
TRAB surgery lowered IOP significantly more than XEN45 implant with or without phacoemulsification over 3 years and had a significantly lower need for additional needling surgery. Both procedures reduced glaucoma medications to a similar rate. These findings are relevant to the informed consent process and patient decisions for one procedure over the other.
小梁切除术(TRAB)在3年时间里降低眼压(IOP)的效果优于XEN45植入术。两种手术使用的抗青光眼药物数量没有差异。必须根据具体情况评估进行TRAB手术或XEN45植入术的决定,同时要考虑到XEN45的针刺率较高。
本研究的目的是比较XEN45植入术与TRAB手术单独或联合白内障超声乳化术(PHACO)治疗开角型青光眼(OAG)患者36个月时的疗效和安全性差异。
对2016年至2018年接受XEN45植入术或TRAB手术的OAG患者进行一项回顾性、单中心比较研究。患者分为4组:第1组(单独XEN45)、第2组(XEN45+PHACO)、第3组(单独TRAB)和第4组(TRAB+PHACO)。为了进行统计,将第1组和第2组合并(XEN45植入术),而第3组和第4组也合并(TRAB手术)。评估眼压、青光眼药物数量和不良事件。主要观察指标是术后36个月时眼压的降低情况。
纳入134例患者(134只眼;63只接受XEN45植入术,71只接受TRAB手术)。研究随访结束时眼压降低的平均值(95%置信区间)为-6.3(-11.0至-1.6 mmHg,P =0.025,单独XEN45)、-8.9(-11.0至-6.8 mmHg,P <0.001,单独TRAB)、-2.5(-4.5至-0.4 mmHg,P =0.019,XEN45+PHACO)和-5.6(-7.7至-3.4 mmHg,P <0.001,TRAB±PHACO)。在36个月随访结束时,未接受治疗眼压≥6且≤16 mmHg的患者比例在XEN45植入术组为50.8%(32/63),在TRAB手术组为49.3%(35/71),P =0.863。所有研究组青光眼药物的平均数量均显著减少。XEN45的针刺率为19%,而TRAB组为5.6%(P =0.030),TRAB组分别有2.81%和36.6%的眼睛出现前房变平和前房积血。
在3年时间里,无论是否联合白内障超声乳化术,TRAB手术降低眼压的效果均显著优于XEN45植入术,且额外针刺手术的需求显著更低。两种手术降低青光眼药物的比例相似。这些发现与知情同意过程以及患者对一种手术优于另一种手术的决策相关。